Drugs / NOVOCART 3D
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03219307 | Nov 2018 → Jan 2026 overdue | articular cartilage disorder | Aesculap Biologics, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01957722 | Dec 2013 → Dec 2025 overdue | — | Aesculap Biologics, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NOVOCART 3D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01957722 ↗ |
| Modality | Cell therapy | “combination product- biologic (autologous chondrocytes) /device (scaffold) implant” NCT01957722 ↗ |